Gyula Végsõ,Laura Fekete,Imre Fehérvári et al.
Gyula Végsõ et al.
Surgical treatment of liver metastases, under certain conditions, can be a step of a multidisciplinary treatment strategy for advanced malignant disease. Nevertheless, it is not the same if metachronous or synchronous metastases are planned...
Review
Magyar onkologia. 2018 Mar 23;62(1):29-36. DOI: 2018
Imre Fehérvári,László Piros,Gyula Végsõ et al.
Imre Fehérvári et al.
The indications for liver transplantation have become generally accepted over the last decades. However, in the last ten years, this indication area changes, it seems to be enlarged. Increasingly, previously classified as contraindications ...
Review
Magyar onkologia. 2018 Mar 23;62(1):26-28. DOI: 2018
Attila Szijártó,András Fülöp
Attila Szijártó
The incidence of primary malignant liver tumours is globally rising. Hepatocellular carcinoma constitutes 75-85% of primary liver malignancies. Owing to advancements of oncological therapies, several methods are available to combat the tumo...
Review
Magyar onkologia. 2018 Mar 23;62(1):14-25. DOI: 2018
Gergely Nagy,Katalin Dezsõ,Gergely Kiss et al.
Gergely Nagy et al.
The most common benign liver tumours are haemangiomas, focal nodular hyperplasia and hepatocellular adenoma. We perform a review of the literature and show the current diagnostic and therapeutic modalities based on the EASL Clinical Practic...
Review
Magyar onkologia. 2018 Mar 23;62(1):5-13. DOI: 2018
[Stereotactic ablative body radiotherapy (SABRT) for locally advanced pancreatic cancer. Case report and review of literature] [0.03%]
stereotactic ablative body radiotherapy (SABRT)治疗局部晚期胰腺癌一例及文献复习
Gerda Földi,Zsuzsánna Zongor,Csaba Polgár et al.
Gerda Földi et al.
Pancreatic cancer has one of the worst outcomes among malignant tumors. At the time of diagnosis only 20% of the cases are resectable and 30-50% are locally advanced, when curative intervention cannot be performed. After resection local rel...
András Jeney,Judit Kralovánszky,Károly Lapis
András Jeney
The present review about the history of anticancer drug research in Hungary intends to call attention to the importance of studies on their mode of action. Several lines of evidence suggest that clinically usable oncopharmacological propert...
[Epidemiology of soft tissue sarcomas in a university center in Hungary] [0.03%]
匈牙利一家大学中心的软组织肉瘤流行病学
Maysam Amin Moghaddam,Tamás Perlaky,Krisztián Kovács et al.
Maysam Amin Moghaddam et al.
Our aim was to investigate the rare malignant soft tissue sarcomas responsible for 1.5% of all malignant tumors, to compare our epidemiological data from the patient population of the Department of Orthopaedics, Semmelweis University, to da...
Comparative Study
Magyar onkologia. 2017 Dec 18;61(4):368-373. DOI: 2017
[Quality and performance indicators of the pilot program for cervical cancer screening by health visitors] [0.03%]
〔访视护士从事子宫颈癌筛检计划之品质与绩效指标〕
Réka Vajda,Csilla Árváné Egri,Attila Kovács et al.
Réka Vajda et al.
The aim of our analysis was the assessment of the qualitative and performance indicators of a pilot program for health visitors' cervical cancer screening. The analysis involved the data from the Communication module of the Office of the Na...
[Experience with cabazitaxel therapy for patients with metastatic castrate resistant prostate cancer in Hungary] [0.03%]
匈牙利转移性去势抵抗性前列腺癌患者多西他赛治疗后的卡巴他赛治疗经验
Anikó Maráz,Katalin Boér,Zsófia Dankovics et al.
Anikó Maráz et al.
Our aim was to assess the efficacy and adverse effects of cabazitaxel (CBZ), a chemotherapeutic agent that can be administered to patients with metastatic castrate resistant prostate cancer (mCRPC) after docetaxel (DOC) therapy. We retrospe...
Multicenter Study
Magyar onkologia. 2017 Dec 18;61(4):353-360. DOI: 2017
[The post-treatment cognitive impairment ("chemobrain") in breast cancer patients. Short review] [0.03%]
乳腺癌患者化疗后的认知功能损害（“化疗脑”）的短篇综述
Tamás Nagykálnai,László Landherr
Tamás Nagykálnai
With the continually growing number of cancer survivors in the past decades there is an increased interest in understanding and treating the adverse events of cancer therapy, which damage the survivor's quality of life. Post-treatment cogni...